TY - JOUR
T1 - The rise of new technologies for aortic valve stenosis: A comparison of sutureless and transcatheter aortic valve implantation
AU - D'Onofrio, Augusto
AU - Salizzoni, Stefano
AU - Rubino, Antonino S.
AU - Besola, Laura
AU - Filippini, Claudia
AU - Alfieri, Ottavio
AU - Colombo, Antonio
AU - Agrifoglio, Marco
AU - Fischlein, Theodor
AU - Rapetto, Filippo
AU - Tarantini, Giuseppe
AU - Dalèn, Magnus
AU - Gabbieri, Davide
AU - Meuris, Bart
AU - Savini, Carlo
AU - Gatti, Giuseppe
AU - Aiello, Marco Luigi
AU - Biancari, Fausto
AU - Livi, Ugolino
AU - Stefàno, Pier Luigi
AU - Cassese, Mauro
AU - Borrello, Bruno
AU - Rinaldi, Mauro
AU - Mignosa, Carmelo
AU - Gerosa, Gino
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Objective Transcatheter aortic valve implantation (TAVI) and sutureless aortic valve replacement (SU-AVR) are suitable alternatives to conventional surgery. The aim of this study is to compare early outcomes of patients undergoing TAVI and SU-AVR. Methods Data were analyzed on patients who underwent TAVI and patients who underwent SU-AVR. Two matched cohorts (TAVI vs SU-AVR) were created using propensity scores; all analyses were repeated for transapical TAVI and transfemoral TAVI, separately. Outcomes were defined according to Valve Academic Research Consortium-2 criteria. Results A total of 2177 patients were included in the analysis: 1885 (86.6%) treated with TAVI; 292 (13.4%) treated with SU-AVR. Mortality in unmatched TAVI and SU-AVR patients was 7.1% and 2.1%, respectively, at 30 days, and 12.9% and 4.6%, respectively, at 1 year. No differences were found in 30-day mortality in the 214 matched patient pairs (3.7% vs 2.3%; P =.4), but patients treated with TAVI showed a lower incidence of device success (85.9% vs 98.6%; P
AB - Objective Transcatheter aortic valve implantation (TAVI) and sutureless aortic valve replacement (SU-AVR) are suitable alternatives to conventional surgery. The aim of this study is to compare early outcomes of patients undergoing TAVI and SU-AVR. Methods Data were analyzed on patients who underwent TAVI and patients who underwent SU-AVR. Two matched cohorts (TAVI vs SU-AVR) were created using propensity scores; all analyses were repeated for transapical TAVI and transfemoral TAVI, separately. Outcomes were defined according to Valve Academic Research Consortium-2 criteria. Results A total of 2177 patients were included in the analysis: 1885 (86.6%) treated with TAVI; 292 (13.4%) treated with SU-AVR. Mortality in unmatched TAVI and SU-AVR patients was 7.1% and 2.1%, respectively, at 30 days, and 12.9% and 4.6%, respectively, at 1 year. No differences were found in 30-day mortality in the 214 matched patient pairs (3.7% vs 2.3%; P =.4), but patients treated with TAVI showed a lower incidence of device success (85.9% vs 98.6%; P
KW - aortic valve replacement
KW - heart valve replacement
KW - heart valve replacement sutureless
KW - percutaneous
KW - transapical
UR - http://www.scopus.com/inward/record.url?scp=84958259866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958259866&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2015.11.041
DO - 10.1016/j.jtcvs.2015.11.041
M3 - Article
VL - 152
SP - 99
EP - 109
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
SN - 0022-5223
IS - 1
ER -